+ News&Events
 
Home News&Events News
News
Hepatitis C drug telaprevir FDA clearance to market
2011-9-16

U.S. FDA approved hepatitis C drug telaprevir
 May 13, FDA approved Merck's Victrelis (Wei Bethsaida horses, boceprevir), just two weeks, that is, May 23, another hepatitis C drug Incivek (telaprevir, Tel horse Wei) allowed . Both drugs belong to a class of so-called protease inhibitors, the inhibitors can prevent hepatitis C virus replication. Incivek Vertex Pharmaceuticals, developed by the United States, it also required with pegylated α-interferon and ribavirin combined.
 According to the U.S. Centers for Disease Control and Prevention (CDC) statistics, an estimated 3.2 million Americans have chronic hepatitis C. Hepatitis C can lead to liver dysfunction or failure. Most people have no symptoms early, until finally liver failure. In the United States most of the implementation of liver transplantation are caused because of this virus. Infection can also cause cancer. Hepatitis C virus is mainly transmitted through blood and sexual contact. In 2250 have never done therapy or conventional therapy not effective in patients with hepatitis C were studied for Telaprevir. Α-interferon with polyethylene glycol and combined with ribavirin, which can continue to produce virus inhibition, 79% of patients cured, rather than just accept the standard pegylated α-interferon treatment in patients with higher than 45%. In the 24 weeks to achieve a sustained response, while conventional therapy to 48 weeks to achieve a sustained response.
 Telaprevir with standard treatment combined with the most common side effects include rash, anemia, nausea, fatigue, headache, diarrhea, anal itching, rectal irritation and pain. Rash may be more severe, eventually resulting in the need to stop using all three drugs. Vertex said it would have no health insurance and annual household income of less than $ 100,000 to provide drugs free of charge. For those who have personal medical insurance accounts, regardless of family income that the company will offer to pay part of the common drugs of up to 20%. The company will also donate to a specific fund to help those in government-insured patients with hepatitis C treatment.



[ Back ]
 
Latest Catalog
Main products
Contact Us
Tel: +86-576-88813233
Tel: +86-576-88205808
Fax: +86-576-88229589
Sales Department:
sales@pharm-intermediates.com
crene.pharm@gmail.com
order@pharm-intermediates.com
Msn:
Skype: Call me!
yahoo:
Homepage | About Us | Products | News&Events | Custom Synthesis | Order Infomation | Contact Us
Friendly link: molbase    molbase    Copyright © Taizhou Crene Biotechnology Co.,Ltd.